Key result
Biochemical analysis suggests that the metavinculin tail domain has impaired binding to acidic phospholipids and reduced homodimerization, requiring vinculin to fully activate the molecule.
Metavinculin requires vinculin for full activation and heterodimer formation, suggesting a cooperative mechanism for modulating microfilament anchorage at muscular adhesion sites that may be relevant to hereditary idiopathic dilated cardiomyopathy.
Does not explain DCM via altered actin binding in vitro; leaves open metavinculin-specific roles in muscle adhesion sites.
Metavinculin, the muscle-specific splice variant of the cell adhesion protein vinculin, is characterized by a 68-amino acid insert within the C-terminal tail domain. The findings that mutations within this region correlate with hereditary idiopathic dilated cardiomyopathy in man suggest a specific contribution of metavinculin to the molecular architecture of muscular actin-membrane attachment sites, the nature of which, however, is still unknown. In mice, metavinculin is expressed in smooth and skeletal muscle, where it co-localizes with vinculin in dense plaques and costameres, respectively, but is of conspicuously low abundance in the heart. Immunoprecipitates suggest that both isoforms are present in the same complex. On the molecular level, both vinculin isoforms are regulated via an intramolecular head-tail interaction, with the metavinculin tail domain having a lower affinity for the head as compared with the vinculin tail. In addition, metavinculin displays impaired binding to acidic phospholipids and reduced homodimerization. Only in the presence of phospholipid-activated vinculin tail, the metavinculin tail domain is readily incorporated into heterodimers. Mutational analysis revealed that the metavinculin insert significantly alters binding of the C-terminal hairpin loop to acidic phospholipids. In summary, our data lead to a model in which unfurling of the metavinculin tail domain is impaired by the negative charges of the 68-amino acid insert, thus requiring vinculin to fully activate the metavinculin molecule. As a consequence, microfilament anchorage may be modulated at muscular adhesion sites through heterodimer formation.
No takes yet. Share an insight, caveat, or question.
Witt et al. (2004) studied this question. Metavinculin and vinculin interaction was evaluated on Biochemical properties and interaction of metavinculin and vinculin. Biochemical analysis suggests that the metavinculin tail domain has impaired binding to acidic phospholipids and reduced homodimerization, requiring vinculin to fully activate the molecule.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: